Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
Sánchez LM, Nieves RM, Latham T, Stuber S, Luden JR, Urcuyo GS, Berges ME, Florencio C, Gonzalez C, Del Villar P, Lane A, Schultz W, Jeste N, Mena R, Ware RE. Sánchez LM, et al. Among authors: latham t. Blood Adv. 2018 Nov 30;2(Suppl 1):50-53. doi: 10.1182/bloodadvances.2018GS110818. Blood Adv. 2018. PMID: 30504201 Free PMC article. Clinical Trial. No abstract available.
Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
McGann PT, Tshilolo L, Santos B, Tomlinson GA, Stuber S, Latham T, Aygun B, Obaro SK, Olupot-Olupot P, Williams TN, Odame I, Ware RE; REACH Investigators. McGann PT, et al. Among authors: latham t. Pediatr Blood Cancer. 2016 Jan;63(1):98-104. doi: 10.1002/pbc.25705. Epub 2015 Aug 14. Pediatr Blood Cancer. 2016. PMID: 26275071 Free PMC article.
EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia.
Rankine-Mullings AE, Little CR, Reid ME, Soares DP, Taylor-Bryan C, Knight-Madden JM, Stuber SE, Badaloo AV, Aldred K, Wisdom-Phipps ME, Latham T, Ware RE. Rankine-Mullings AE, et al. Among authors: latham t. JMIR Res Protoc. 2016 Sep 12;5(3):e185. doi: 10.2196/resprot.5872. JMIR Res Protoc. 2016. PMID: 27619954 Free PMC article.
Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
McGann PT, Williams TN, Olupot-Olupot P, Tomlinson GA, Lane A, Luís Reis da Fonseca J, Kitenge R, Mochamah G, Wabwire H, Stuber S, Howard TA, McElhinney K, Aygun B, Latham T, Santos B, Tshilolo L, Ware RE; REACH Investigators. McGann PT, et al. Among authors: latham t. Am J Hematol. 2018 Aug;93(4):537-545. doi: 10.1002/ajh.25034. Epub 2018 Jan 27. Am J Hematol. 2018. PMID: 29318647 Free PMC article. Clinical Trial.
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators. Tshilolo L, et al. Among authors: latham ts. N Engl J Med. 2019 Jan 10;380(2):121-131. doi: 10.1056/NEJMoa1813598. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501550 Free PMC article. Clinical Trial.
Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
Meier ER, Creary SE, Heeney MM, Dong M, Appiah-Kubi AO, Nelson SC, Niss O, Piccone C, Quarmyne MO, Quinn CT, Saving KL, Scott JP, Talati R, Latham TS, Pfeiffer A, Shook LM, Vinks AA, Lane A, McGann PT. Meier ER, et al. Among authors: latham ts. Trials. 2020 Nov 27;21(1):983. doi: 10.1186/s13063-020-04912-z. Trials. 2020. PMID: 33246482 Free PMC article.
471 results